73 related articles for article (PubMed ID: 27648841)
1. Comparison of the Therapeutic Efficacy of the Early and the Delayed Use of Vinorelbine-Based Regimens for Patients with Advanced Breast Cancer.
Wang Y; Liu J; Jia W; Li S; Rao N; Su F; Liu Q; Yao H
Chemotherapy; 2017; 62(1):71-79. PubMed ID: 27648841
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of utidelone plus capecitabine in advanced first-line therapy for metastatic breast cancer: A multicenter real-world study.
Bi P; Wang X; Liu R; Li X; Wei S; Zhao J; Tan X; Zhang F; Mao Q; Zhang Y; Tang B; Xun X; Guo R; Zheng K; Zhou S; Tang S
Surg Open Sci; 2023 Dec; 16():171-183. PubMed ID: 38026829
[TBL] [Abstract][Full Text] [Related]
3. Nimotuzumab-vinorelbine combination therapy versus other regimens in the treatment of pediatric diffuse intrinsic pontine glioma.
Özkan A; Yağcı Küpeli B; Küpeli S; Sezgin G; Bayram İ
Childs Nerv Syst; 2024 Jun; 40(6):1671-1680. PubMed ID: 38478066
[TBL] [Abstract][Full Text] [Related]
4. A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment.
Du F; Yuan P; Zhao ZT; Yang Z; Wang T; Zhao JD; Luo Y; Ma F; Wang JY; Fan Y; Cai RG; Zhang P; Li Q; Song YM; Xu BH
Sci Rep; 2016 Sep; 6():33825. PubMed ID: 27650797
[TBL] [Abstract][Full Text] [Related]
5. Brain metastases from breast cancer during pregnancy.
Sharma A; Nguyen HS; Lozen A; Sharma A; Mueller W
Surg Neurol Int; 2016; 7(Suppl 23):S603-6. PubMed ID: 27656319
[TBL] [Abstract][Full Text] [Related]
6. Receptor conversion in metastatic breast cancer: a prognosticator of survival.
Meng X; Song S; Jiang ZF; Sun B; Wang T; Zhang Sh; Wu Sh
Oncotarget; 2016 Nov; 7(44):71887-71903. PubMed ID: 27655689
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States.
Diaby V; Adunlin G; Ali AA; Zeichner SB; de Lima Lopes G; Kohn CG; Montero AJ
Breast Cancer Res Treat; 2016 Nov; 160(1):187-196. PubMed ID: 27654970
[TBL] [Abstract][Full Text] [Related]
8. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
Price T; Kim TW; Li J; Cascinu S; Ruff P; Suresh AS; Thomas A; Tjulandin S; Guan X; Peeters M
Eur J Cancer; 2016 Nov; 68():51-59. PubMed ID: 27716478
[TBL] [Abstract][Full Text] [Related]
9. Re-188 Enhances the Inhibitory Effect of Bevacizumab in Non-Small-Cell Lung Cancer.
Xiao J; Xu X; Li X; Li Y; Liu G; Tan H; Shen H; Shi H; Cheng D
Molecules; 2016 Sep; 21(10):. PubMed ID: 27706035
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK
J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268
[TBL] [Abstract][Full Text] [Related]
11. Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives.
Schettini F; Giuliano M; De Placido S; Arpino G
Cancer Treat Rev; 2016 Nov; 50():129-141. PubMed ID: 27665540
[TBL] [Abstract][Full Text] [Related]
12. EGFR gene copy number as a predictive/biomarker for patients with non-small-cell lung cancer receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis.
Zhang X; Zhang Y; Tang H; He J
J Investig Med; 2017 Jan; 65(1):72-81. PubMed ID: 27664271
[TBL] [Abstract][Full Text] [Related]
13. Cystic brain metastasis is associated with poor prognosis in patients with advanced breast cancer.
Sun B; Huang Z; Wu S; Ding L; Shen G; Cha L; Wang J; Song S
Oncotarget; 2016 Nov; 7(45):74006-74014. PubMed ID: 27659537
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement.
Zhang L; Jiang T; Zhao C; Li W; Li X; Zhao S; Liu X; Jia Y; Yang H; Ren S; Zhou C
Oncotarget; 2016 Nov; 7(46):75145-75154. PubMed ID: 27738334
[TBL] [Abstract][Full Text] [Related]
15. Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.
Lam SW; Frederiks CN; van der Straaten T; Honkoop AH; Guchelaar HJ; Boven E
Br J Cancer; 2016 Nov; 115(11):1335-1342. PubMed ID: 27736846
[TBL] [Abstract][Full Text] [Related]
16. Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer.
Li H; Stokes W; Chater E; Roy R; de Bruin E; Hu Y; Liu Z; Smit EF; Heynen GJ; Downward J; Seckl MJ; Wang Y; Tang H; Pardo OE
Cell Discov; 2016; 2():16031. PubMed ID: 27721983
[TBL] [Abstract][Full Text] [Related]
17. Combination Chemotherapy of Mitomycin C and Methotrexate Was Effective on Metastatic Breast Cancer Resistant to Eribulin, Vinorelbine, and Bevacizumab after Anthracycline, Taxane, and Capecitabine.
Tanabe M
Case Rep Oncol; 2016; 9(2):422-426. PubMed ID: 27721762
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of nedaplatin, pemetrexed and thoracic intensity-modulated radiotherapy for inoperable stage III lung adenocarcinoma.
Lu Y; Gu W; Deng J; Yang H; Yang W
BMC Cancer; 2016 Oct; 16(1):775. PubMed ID: 27717315
[TBL] [Abstract][Full Text] [Related]
19. Identification of gene-drug interactions that impact patient survival in TCGA.
Spainhour JC; Qiu P
BMC Bioinformatics; 2016 Oct; 17(1):409. PubMed ID: 27716027
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab for non-small-cell lung cancer: A nested case control study of risk factors for hemoptysis.
Goto K; Endo M; Kusumoto M; Yamamoto N; Ohe Y; Shimizu A; Fukuoka M
Cancer Sci; 2016 Dec; 107(12):1837-1842. PubMed ID: 27714941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
